This protocol applies to patients with somatostatinoma in whom disease remains localized — without evidence of metastatic spread. In this specific setting, the presence or absence of distant disease fundamentally shapes the available therapeutic options.
The patient has somatostatinoma confined to the primary site, with no metastatic disease identified. Localized disease defines both the curative intent of management and the selection of therapeutic strategy.
Management in this setting includes a surgical component directed at the primary tumor, alongside medical therapy intended to address circulating hormone levels and symptom burden. The full protocol specifies the agents, sequencing criteria, and decision points involved.
Decreased fasting serum somatostatin levels and improvement in the severity of symptoms.
DOI: 10.1007/978-3-319-98497-1_117